New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTBDX, ABT, RHHBY, ILMN, A, ENZ, LMNX, HOLX, AFFX, SIEGY, LIFEEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
October 4, 2015
14:39 EDTRHHBYPTC presents Phase 2 data on RG7800 for spinal muscular atrophy
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
08:49 EDTILMNIllumina price target lowered to $220 from $300 at Cowen
Subscribe for More Information
October 1, 2015
10:00 EDTILMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AGCO (AGCO) downgraded to Sell from Neutral at UBS... Banco Santander (SAN) downgraded to Neutral from Overweight at JPMorgan... Crocs (CROX) downgraded to Neutral from Overweight at Piper Jaffray... EZchip (EZCH) downgraded to Hold from Buy at Brean Capital... Illumina (ILMN) downgraded to Market Perform from Outperform at Leerink... ServisFirst (SFBS) downgraded to Hold from Buy at Sandler O'Neill.
06:59 EDTILMNIllumina downgraded to Market Perform from Outperform at Leerink
Leerink analyst Daniel Leonard downgraded Illumina to Market Perform citing a less compelling risk/reward over the next 12 months amid uncertainty regarding the next driver of growth in research. The analyst cut his price target for shares to $185 from $225.
September 30, 2015
20:04 EDTILMNAmoy, Illumina enter into strategic collaboration
Amoy Diagnostics and Illumina (ILMN) announced a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China. Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina's next-generation sequencing platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration reflects the commitment of both companies to provide integrated solutions to meet clinical needs in China.
17:48 EDTRHHBYPacific Biosciences launches new sequencing platform
Subscribe for More Information
September 29, 2015
14:40 EDTILMNIllumina volatility increase on wide share price movement
Subscribe for More Information
September 28, 2015
10:43 EDTRHHBYRoche to hold an analyst briefing with a conference call hookup
Subscribe for More Information
07:52 EDTRHHBYIIR Holdings to hold a conference
Subscribe for More Information
05:15 EDTRHHBYGenentech announces Phase III study of ocrelizumab met primary endpoint
Subscribe for More Information
September 27, 2015
17:02 EDTRHHBYNewLink Genetics reports early Phase 1a data on GDC-0919
Subscribe for More Information
16:42 EDTRHHBYRoche present Phase 2 results on atezolizumab for urothelial cancer
Subscribe for More Information
16:40 EDTRHHBYRoche reports results from two Phase 2 studies on atezolizumab
Genentech, a member of the Roche Group, announced results from two Phase 2 studies that evaluated the investigational cancer immunotherapy atezolizumab -- or anti-PDL1; MPDL3280A -- in people with advanced non-small cell lung cancer. In the randomized Phase 2 study POPLAR, atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to chemotherapy in people with recurrent NSCLC whose tumors expressed medium and high levels of PD-L1, which corresponded with people living 7.7 months longer than people who received docetaxel chemotherapy. A separate, single-arm Phase 2 study, BIRCH, met its primary endpoint and showed that atezolizumab shrank tumors in up to 27% of people whose disease had progressed on prior medicines and also expressed the highest levels of PD-L1. Median survival had not yet been reached. In both studies of atezolizumab, adverse events were consistent with those observed in previous studies. "We plan to submit these results to global health authorities to bring this potential new option to people as soon as possible," said Chief Medical Officer Sandra Horning.
September 25, 2015
12:53 EDTLMNXLuminex management to meet with William Blair
Meeting to be held in Chicago on September 30 hosted by William Blair.
07:42 EDTRHHBYExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTRHHBYEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
06:23 EDTRHHBYRoche CEO: Will see growth regardless of setbacks, Reuters reports
Roche Holding's product lineup is so good that the company will see growth regardless of setbacks, Reuters reports, citing an interview with CEO Severn Schwan with Finanz und Wirtschaft. "Roche could have six new active pharmaceutical ingredients approved within two years. We never had this before," Schwan said. Reference Link
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use